Avivomed Names Dan Brounstein as Next Chief Executive Officer

Appointment to Accelerate Mission of Pioneering Innovative Neuromodulation Therapies to Improve Quality of Life by Restoring Sleep

MINNEAPOLIS, June 26, 2025 /PRNewswire/ -- Avivomed, Inc., a privately held, clinical-stage, medical device company, announced the appointment of Dan Brounstein as its new Chief Executive Officer and Board Member. Brounstein succeeds CEO Steve Masson, who retired from his role in May and will continue to work with the company in an advisory role.

"Millions struggle with interrupted sleep, and current treatments often fall short. Dan's extensive background in neuromodulation and strong leadership skills, in developing and launching innovative medical therapies, make him the ideal leader for Avivomed and its next development," said Mudit K. Jain, PhD, Co-founder and Chair of Avivomed's Board of Directors. "On behalf of the entire Board, I want to thank Steve for his dedication which led to impressive milestones reached under his tenure."

With more than 30 years of experience, Brounstein is a successful medical device veteran with proven leadership across commercialization, clinical execution, research and development, and reimbursement in the medical device industry. Prior to joining Avivomed, he served as Chief Strategy Officer at Saluda Medical, leading the landmark Evoke Pivotal Study and launching the Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulator to treat chronic pain. In previous roles, he held various leadership positions including Vice President of Marketing and Clinical Operations at Spinal Modulation, where he led strategy to bring DRG Stimulation to market, culminating in acquisition by St. Jude Medical (now Abbott). He holds a Bachelor of Science in Bioengineering from UC San Diego and an MBA from UC Berkeley's Haas School of Business.

About Avivomed, Inc.
Avivomed is a pioneering medical device company dedicated to developing next generation minimally invasive neuromodulation therapies aimed at improving quality of life for patients suffering from obstructive sleep apnea. Building on the NuXcel innovation ecosystem, Avivomed is a Minneapolis-based company backed by investors including F-Prime, Hatteras Venture Partners, Treo Ventures, Norwest, and others. For more information, visit avivomed.com.

Contact
Lisa Keathly
[email protected]

SOURCE Avivomed, Inc.